Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Dumont & Blake Investment Advisors LLC

Dumont & Blake Investment Advisors LLC cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,275 shares of the medical research company’s stock after selling 85 shares during the period. Dumont & Blake Investment Advisors LLC’s holdings in Charles River Laboratories International were worth $789,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in CRL. Versant Capital Management Inc lifted its stake in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Wolff Wiese Magana LLC acquired a new stake in Charles River Laboratories International in the third quarter valued at $32,000. Pinnacle Bancorp Inc. grew its holdings in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the last quarter. Assetmark Inc. grew its holdings in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares during the last quarter. Finally, ORG Wealth Partners LLC purchased a new position in shares of Charles River Laboratories International during the fourth quarter worth about $56,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Price Performance

NYSE CRL opened at $165.38 on Friday. Charles River Laboratories International, Inc. has a twelve month low of $159.65 and a twelve month high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The stock has a market capitalization of $8.46 billion, a PE ratio of 20.70, a P/E/G ratio of 5.94 and a beta of 1.38. The stock has a 50-day simple moving average of $184.77 and a 200 day simple moving average of $196.03.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter in the prior year, the firm posted $2.72 EPS. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. Research analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on CRL. Redburn Atlantic assumed coverage on Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 price target on the stock. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a research report on Monday, November 18th. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. UBS Group restated a “neutral” rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Finally, The Goldman Sachs Group lowered their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $204.38.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).